Abstract:The efficacy of anti-VEGF agents probably lies on VEGF-dependency. Apatinib, a specific tyrosine kinase inhibitor that targets VEGF receptor 2, was assessed in patients with advanced breast cancer (ABC) (ClinicalTrials.gov NCT01176669 and NCT01653561). This substudy was to explore the potential biomarkers for VEGF-dependency in apatinib-treated breast cancer. Eighty pretreated patients received apatinib 750 or 500 mg/day orally in 4-week cycles. Circulating biomarkers were measured using a multiplex assay, and tissue biomarkers were identified with immunostaining. Baseline characteristics and adverse events (AEs) were included in the analysis. Statistical confirmation of independent predictive factors for anti-tumor efficacy was performed using Cox and Logistic regression models. Median progression-free survival (PFS) was 3.8 months, and overall survival (OS) was 10.6 months, with 17.5 % of objective response rate. Prominent AEs (≥60 %) were hypertension, hand-foot skin reaction (HFSR), and proteinuria. Higher tumor phosphorylated VEGFR2 (p-VEGFR2) expressions ( P = 0.001), higher baseline serum soluble VEGFR2 ( P = 0.031), hypertension ( P = 0.011), and HFSR ( P = 0.018) were significantly related to longer PFS, whereas hypertension ( P = 0.002) and HFSR ( P = 0.001) were also related to OS. Based on multivariate analysis, only p-VEGFR2 (adjusted HR, 0.40; P = 0.013) and hypertension (adjusted HR, 0.58; P = 0.038) were independent predictive factors for both PFS and clinical benefit rate. Apatinib had substantial antitumor activity in ABC and manageable toxicity. p-VEGFR2 and hypertension may be surrogate predictors of VEGF-dependency of breast cancer, which may identify an anti-angiogenesis sensitive population.

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

sFlt-1: A Double Regulator in Angiogenesis-related Diseases

Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications

Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1

Tumor Cell-Derived Placental Growth Factor Sensitizes Antiangiogenic and Antitumor Effects of Anti-Vegf Drugs

Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Inhibition of Ovarian Tumor Growth by Gene Therapy with Recombinant Soluble Vascular Endothelial Growth Factor Receptor 2.

HER2-targeted Tumor immunotherapy

Progression of VEGF-targeted cancer therapy

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

Recent Advances in Antiangiogenic Agents with VEGFR As Target

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Vegfr Inhibitors As Sensitizing Agents For Cancer Chemotherapy

Research Advance in Vascular Endothelial Growth Factor and Anti-Tumor

Angiogenic signaling pathways and anti-angiogenic therapy for cancer